GXO Logistics Inc vs TG Therapeutics Inc — how do they compare? GXO Logistics Inc trades at $52.8 (market cap $6.07B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| GXO | TGTX | |
|---|---|---|
Market Cap | $6.07B | $8.26B |
Sector | Industrials | Health |
52-Week High | $65.59 | $59.06 |
52-Week Low | $45.52 | $26.39 |
Enterprise Value | $11.24B | $8.50B |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $52.80, down 2.31% today, with strong analyst support showing 16 buy ratings and an average price target of $66.60. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.50 surpassing the $0.37 estimate. Technical indicators show a bullish trend with moving averages supporting upward momentum, while fundamentals reveal revenue growth to $13.18 billion in 2025 with improving profitability margins expected in 2026.
GXO presents a compelling investment case with 36% upside to consensus targets, supported by strong earnings momentum and expanding partnerships. Key risks include competitive pressures in logistics and Amazon's market entry, while the company's focus on high-growth verticals and record sales pipeline provides growth catalysts. The stock's current valuation at 48.26 P/E requires continued execution to justify premium multiples.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →